Janssen/Legend Plan Phased US Launch For BCMA-Targeting CAR-T Carvykti
First Multiple Myeloma Patient Could Be Infused In Six Weeks
Executive Summary
Janssen priced the one-time autologous treatment at $465,000, well above the $419,500 list price for Bristol’s first-to-market CAR-T, but expects broad commercial and Medicare coverage.
You may also be interested in...
J&J/Legend’s Carvykti Data Show Earlier-Line Efficacy As Commercial Headwinds Remain
The companies unblinded data from CARTITUDE-4, which met its primary endpoint, but analysts citing KOLs said they continue to face issues with limited manufacturing slots and out-of-spec product.
Genentech Licenses Prostate Cancer Drug From China-Based Jemincare
Deal Snapshot: Other major players have made headway in bispecifics for prostate cancer, while Jemincare’s drug is the latest China-developed technology to head westward.
2seventy/BMS’s Abecma Shines In Earlier Lines, But J&J/Legend’s Carvykti May Have Edge
Without disclosing data, 2seventy and BMS reported positive Phase III results in third-line and beyond multiple myeloma, but Carvykti will soon have second-line data.